> Sounds like textbook comparative advantage, and in any sane market, imports would be about as controversial as paint drying. This isn't comparative advantag

> Sounds like textbook comparative advantage, and in any sane market, imports would be about as controversial as paint drying. This isn't comparative advantage, especially since we're often times talking about reimporting drugs (both brand-name and generics) that were manufactured in the US, but sold abroad for cheaper prices. The article doesn't make that very clear, and I wish it did, because it's an important distinction. But your point is spot on - from a free market standpoint, this is a no-brainer. There is literally no reason to prevent US patients from buying drugs that were manufactured in the US from Canadian or European wholesalers. Except, of course, that this is a massive source of profit for pharmaceutical companies.